Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.83 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.81 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.81 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679287 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2683846 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL285071 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157645 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4071893 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157644 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056922 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056709 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056916 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL317204 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767546-B2 | Enzymatic method for preparation of UDP-GlcNAc | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-09-26 | — | — | US | disclosed |
| EP-3874055-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALACTOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3874056-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | disclosed |
| US-20220389480-A1 | SEPARATION OF NUCLEIC ACID COMPONENT COMPOUNDS ON ZWITTERIONIC STATIONARY PHASES | WATERS TECHNOLOGIES CORPORATION (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220220135-A1 | HIGHLY SELECTIVE AND POTENT NPP1 INHIBITORS BASED ON URIDINE-5'-P,-DITHIOPHOSPHATE ANALOGUES | BAR-ILAN UNIVERSITY (IL) | 2022-07-14 | — | — | US | disclosed |
| EP-3819382-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819381-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALACTOSE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021015622-A1 | SYNTHESIS OF 6-AZIDO-6-DEOXY-2-N-ACETYL-HEXOSAMINE-NUCLEOSIDE DIPHOSPHATE | SYNAFFIX B.V. (NL) | 2021-01-28 | — | — | WO | disclosed |
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION | 2020-07-09 | — | — | US | disclosed |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
| US-9645140-B2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20120219963-A1 | DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS | KING'S COLLEGE LONDON OF STRAND (GB) | 2012-08-30 | — | — | US | disclosed |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7939510-B2 | Di(uridine 5′-)tetraphosphate and salts thereof | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2010015245-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20090326050-A1 | DI(URIDINE 5'-)TETRAPHOSPHATE AND SALTS THEREOF | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| US-7528119-B2 | Di(uridine 5′-)tetraphosphate and salts thereof | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | TYMP, PNP, NUDT1 | P2RY6 247/4885P2RY2 489/4885P2RY4 272/4885 |
| US-20220220135-A1 | HIGHLY SELECTIVE AND POTENT NPP1 INHIBITORS BASED ON URIDINE-5'-P,-DITHIOPHOSPHATE ANALOGUES | UPP1, NUDT14, UMPS | P2RY6 1256/4885P2RY2 1300/4885P2RY4 1075/4885 |
| US-20090326050-A1 | DI(URIDINE 5'-)TETRAPHOSPHATE AND SALTS THEREOF | UMPS, NUDT1, UPP1 | P2RY6 56/4885P2RY2 222/4885P2RY4 83/4885 |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | PNP, TYMP, DPYD | P2RY6 720/4885P2RY2 1020/4885P2RY4 539/4885 |
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | P2RY6 3600/4885P2RY2 4442/4885P2RY4 4456/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | P2RY6 802/4885P2RY2 1037/4885P2RY4 518/4885 |
| US-20120219963-A1 | DERIVATIVES OF URIDINE PHOSPHATE AND THEIR USES IN PROTEIN BINDING ASSAYS | OGA, OSTC, UPP1 | P2RY6 937/4885P2RY2 1356/4885P2RY4 618/4885 |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | P2RY6 3600/4885P2RY2 4442/4885P2RY4 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.